Wegovy Side Effects UK: Complete Guide to Managing Semaglutide Side Effects

Wegovy (semaglutide 2.4mg) is approved in the UK by the MHRA for chronic weight management in adults with a BMI of 30 or above, or 27+ with at least one weight-related condition. It belongs to the GLP-1 receptor agonist class — medications that mimic the naturally occurring hormone glucagon-like peptide-1, which regulates appetite, gastric emptying, and blood glucose.

Clinical trial data from the STEP programme (the pivotal trials that led to Wegovy's approval) and real-world evidence from millions of users worldwide gives us a clear picture of its side effect profile.

Gastrointestinal side effects affect approximately 80% of users at some point during treatment, though the vast majority are mild to moderate and improve over time. These include:

• •Nausea — the most common side effect, particularly during dose escalation
• •Vomiting — reported by around 24% of users in clinical trials
• •Diarrhoea — common early on and during dose increases
• •Constipation — affects a significant proportion; can alternate with diarrhoea
• •Abdominal pain — often described as cramping or generalised discomfort
• •Belching and flatulence — frequently reported, particularly with certain foods
• •Gastroesophageal reflux (GORD) — worsening of acid reflux in those already prone

Non-GI side effects that users commonly report include: - Fatigue, particularly in the early weeks - Headache during dose escalation - Dizziness, especially with reduced food intake - Injection site reactions (redness, bruising, mild swelling)

*Always consult a healthcare professional before starting Wegovy. This content is for educational purposes only.*

One of the most important pieces of information for people starting Wegovy is the typical resolution timeline. Understanding that side effects are usually time-limited — not permanent — helps many people persevere through the initial difficult period.

The Dose Escalation Schedule: Wegovy is titrated over 16 weeks to reach the maintenance dose of 2.4mg: - Weeks 1–4: 0.25mg weekly - Weeks 5–8: 0.5mg weekly - Weeks 9–12: 1mg weekly - Weeks 13–16: 1.7mg weekly - Week 17 onwards: 2.4mg weekly (maintenance)

This gradual escalation is specifically designed to minimise side effects. Each dose increase typically triggers a short adjustment period.

The 4–8 Week Resolution Pattern: For most users, GI side effects at any given dose level ease within 4–8 weeks. In clinical practice, this means: - The starting dose (0.25mg) causes mild symptoms that resolve within 2–3 weeks for most people - The maintenance dose (2.4mg) adjustment is usually the longest, but the majority of users report significant improvement by 4–6 weeks - After 3–4 months on the full dose, many users experience minimal ongoing GI symptoms

Why Slow Titration Works: The gradual increase allows GLP-1 receptor desensitisation in the gut and brain. Over time, your body adjusts to the slower gastric emptying and changes in appetite signalling.

When Side Effects Don't Resolve: If GI symptoms remain severe after 8 weeks at any dose level, speak to your prescriber. Options include: - Staying at the current dose longer before escalating - Stepping back down to the previous dose temporarily - Investigating whether an underlying condition (e.g. gastroparesis) may be contributing

*Consult your GP or specialist before making any changes to your Wegovy dose or schedule.*

The most powerful tool for managing Wegovy side effects isn't a medication or a dietary supplement — it's how you manage the dose escalation itself. The prescribing guidance allows for flexibility that many patients aren't told about.

You Don't Have to Escalate on Schedule: The standard titration schedule is a minimum — you can remain at any dose for longer than 4 weeks if side effects are significant. There is no clinical benefit to rushing to the maintenance dose faster than your body tolerates. In fact, pushing through severe nausea can lead to: - Dehydration from vomiting - Nutritional deficiencies from severely restricted eating - Electrolyte imbalances - Abandoning treatment altogether

Practical Guidance: - If you're experiencing troublesome nausea at 0.5mg, stay at 0.5mg for an additional 4 weeks before moving to 1mg - If vomiting is frequent (more than 3 times in a week), contact your prescriber — this warrants a dose review, not powering through - Some patients take 6 months or longer to reach 2.4mg; this is entirely acceptable

What the Evidence Shows: The STEP programme data demonstrates that slower titration improves tolerability without significantly reducing efficacy. The weight loss benefits of semaglutide accumulate over months and years — losing a few weeks to better tolerability has negligible impact on long-term outcomes.

Discussing Flexibility with Your Prescriber: If you're accessing Wegovy via an online service, don't hesitate to message your prescribing clinician to request a slower escalation. This is a clinically appropriate and commonly used approach. Your comfort and safety should always take precedence over adherence to a rigid schedule.

*Always discuss any changes to your Wegovy schedule with your healthcare provider.*

In 2023, the MHRA and European Medicines Agency (EMA) launched investigations into reports of suicidal ideation and self-harm thoughts in patients taking semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda/Victoza). This followed reports submitted through pharmacovigilance systems including the UK's Yellow Card scheme.

What the Evidence Currently Shows: As of early 2026, regulators have not established a definitive causal link between semaglutide and suicidal ideation. Key considerations: - People with obesity have higher baseline rates of depression and anxiety independent of medication - Weight loss itself — while generally positive for mental health — can occasionally trigger complex psychological responses, particularly in those with a history of disordered eating - Some individuals experience mood changes related to significant changes in appetite and relationship with food - Clinical trial data from the STEP programme did not show an increased rate of psychiatric events compared to placebo

MHRA's Current Position: The MHRA continues to monitor this signal. As a precaution, Wegovy prescribers are advised to: - Screen patients for a history of depression, anxiety, or suicidal ideation before prescribing - Monitor for any new or worsening mental health symptoms during treatment - Advise patients to report any concerning mood changes promptly

Hair Thinning: Another commonly reported side effect is telogen effluvium — a type of temporary hair shedding triggered by rapid weight loss and reduced calorie intake rather than the medication itself. This typically: - Begins 2–4 months after significant weight loss starts - Resolves within 6–12 months as weight stabilises - Can be minimised by ensuring adequate protein intake (at least 80–100g per day)

*If you experience any concerning changes in mood, thoughts of self-harm, or significant psychological distress while taking Wegovy, contact your GP or call Samaritans on 116 123 immediately. Do not stop your medication without medical guidance.*

While the vast majority of Wegovy users experience only manageable GI side effects, there are serious but rare complications that warrant urgent attention.

Pancreatitis: GLP-1 receptor agonists have a class-level association with pancreatitis risk. Warning signs include: - Severe, persistent upper abdominal pain radiating to the back - Pain significantly worsened after eating - Accompanying nausea and vomiting that doesn't settle

If these symptoms occur, stop Wegovy immediately and attend A&E. Pancreatitis is a medical emergency.

Gallbladder Disease: Rapid weight loss substantially increases gallstone formation risk. Wegovy's STEP trials showed a higher rate of gallbladder-related adverse events compared to placebo. Watch for: - Sharp right-sided or central upper abdominal pain - Pain after fatty meals - Jaundice (yellowing of skin or eyes)

Diabetic Retinopathy: People with type 2 diabetes using semaglutide may experience worsening of diabetic retinopathy, particularly if blood sugar control improves rapidly. If you have diabetes, ensure regular eye screening is maintained.

Thyroid Concerns: Animal studies identified a signal for thyroid C-cell tumours with GLP-1 agonists. Wegovy is contraindicated in those with a personal or family history of medullary thyroid carcinoma or MEN 2. Report any unexplained neck lump, hoarseness, or swallowing difficulty immediately.

Reporting to the MHRA: Report any suspected Wegovy side effects via the Yellow Card scheme at yellowcard.mhra.gov.uk. Patient reports are a critical part of post-marketing surveillance and contribute to improving safety for all users.

*This article is for informational purposes only and does not substitute for professional medical advice. Always consult a qualified healthcare professional before starting, adjusting, or stopping Wegovy. In an emergency, call 999.*